Tikun Europe has announced that it has received a license to start operations on its factory.
Tikun has confirmed that the production process of the final medical cannabis products is expected immediately.
Located in a privately owned area of 56,000m2 in Corinth, the factory is an investment of more than €30m (~£111.17m) euros, and is fully vertically integrated, having an R&D department and high-tech equipment.
CEO of Tikun Europe, Nikos Beis, commented: “It was a great pleasure to welcome the operating licence of our production unit, the construction of which was recently completed.
“The operation of the plant will start very soon, bringing us one step closer to the realisation of our vision: to meet the ever-increasing demand of Greece and Europe for high-quality medical cannabis products.
“Our factory is the largest pharmaceutical company in the specific industry in Europe and exploits the potential of our country to play a leading role in the global market for medical cannabis.”
The factory has three distinct units including a greenhouse cultivation area, a post-harvest processing area and an area designated for the production and packaging of finished medical cannabis products.
The company has stated that the factory complies with the GACP and EU-GMP standards of the European Union and the domestic legislation for the cultivation and processing of medical cannabis, while its operation will be carried out with absolute responsibility and respect for the environment and the local community.
The new production unit was recently visited by the Minister of Development and Investments, Adonis Georgiadis, who confirmed that the Government’s commitment to investments has been implemented, with the plant launching the production process starting July. The Minister’s visit took place at a pivotal moment for the company, following the legislation on medical cannabis and his first tour of the factory that had taken place two years ago.